Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting

Andrea K. Miyahira; Robert B. Den; Maria I. Carlo; Renée de Leeuw; Thomas A. Hope; Fatima Karzai; Rana R. McKay; Simpa S. Salami; Jonathan W. Simons; Kenneth J. Pienta; Howard R. Soule

doi:10.1002/pros.23729

Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting

Andrea K. Miyahira, Robert B. Den, Maria I. Carlo, Renée de Leeuw, Thomas A. Hope, Fatima Karzai, Rana R. McKay, Simpa S. Salami, Jonathan W. Simons, Kenneth J. Pienta, Howard R. Soule

School of Medicine

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Introduction: The 2018 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, “Tumor Cell Heterogeneity and Resistance,” was held in Los Angeles, California from June 21 to 24, 2018. Methods: The CHPCA Meeting is a unique, discussion-oriented scientific conference convened annually by the Prostate Cancer Foundation (PCF), which focuses on the most critical topics in need of further study to advance the treatment of lethal prostate cancer. The 6th Annual CHPCA Meeting was attended by 70 investigators and concentrated on prostate cancer heterogeneity and treatment resistance. Results: The meeting focused on topics including: recognition of tumor heterogeneity, molecular drivers of heterogeneity, the role of the tumor microenvironment, the role of heterogeneity in disease progression, metastasis and treatment resistance, clinical trials designed to target resistance and tumor heterogeneity, and immunotherapeutic approaches to target and overcome tumor heterogeneity. Discussion: This review article summarizes the presentations and discussions from the 2018 CHPCA Meeting in order to share this knowledge with the scientific community and encourage new studies that will lead to improved treatments and outcomes for men with prostate cancer.

Original language	English (US)
Pages (from-to)	244-258
Number of pages	15
Journal	Prostate
Volume	79
Issue number	3
DOIs	https://doi.org/10.1002/pros.23729
State	Published - Feb 15 2019

Keywords

biomarkers
cancer immunotherapy
molecular imaging
therapeutics
tumor genomics

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1002/pros.23729

Cite this

@article{9ae93e2ce10e40eba37fe03d67a2cd02,

title = "Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting",

abstract = "Introduction: The 2018 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, “Tumor Cell Heterogeneity and Resistance,” was held in Los Angeles, California from June 21 to 24, 2018. Methods: The CHPCA Meeting is a unique, discussion-oriented scientific conference convened annually by the Prostate Cancer Foundation (PCF), which focuses on the most critical topics in need of further study to advance the treatment of lethal prostate cancer. The 6th Annual CHPCA Meeting was attended by 70 investigators and concentrated on prostate cancer heterogeneity and treatment resistance. Results: The meeting focused on topics including: recognition of tumor heterogeneity, molecular drivers of heterogeneity, the role of the tumor microenvironment, the role of heterogeneity in disease progression, metastasis and treatment resistance, clinical trials designed to target resistance and tumor heterogeneity, and immunotherapeutic approaches to target and overcome tumor heterogeneity. Discussion: This review article summarizes the presentations and discussions from the 2018 CHPCA Meeting in order to share this knowledge with the scientific community and encourage new studies that will lead to improved treatments and outcomes for men with prostate cancer.",

keywords = "biomarkers, cancer immunotherapy, molecular imaging, therapeutics, tumor genomics",

author = "Miyahira, {Andrea K.} and Den, {Robert B.} and Carlo, {Maria I.} and {de Leeuw}, Ren{\'e}e and Hope, {Thomas A.} and Fatima Karzai and McKay, {Rana R.} and Salami, {Simpa S.} and Simons, {Jonathan W.} and Pienta, {Kenneth J.} and Soule, {Howard R.}",

note = "Funding Information: M.I.C. has served an advisory role for Pfizer. R.R.M. has served on the Advisory Board for Janssen, Novartis, and Tempus, and has received research funding from Bayer and Pfizer. Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",

year = "2019",

month = feb,

day = "15",

doi = "10.1002/pros.23729",

language = "English (US)",

volume = "79",

pages = "244--258",

journal = "Prostate",

issn = "0270-4137",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting

AU - Miyahira, Andrea K.

AU - Den, Robert B.

AU - Carlo, Maria I.

AU - de Leeuw, Renée

AU - Hope, Thomas A.

AU - Karzai, Fatima

AU - McKay, Rana R.

AU - Salami, Simpa S.

AU - Simons, Jonathan W.

AU - Pienta, Kenneth J.

AU - Soule, Howard R.

N1 - Funding Information: M.I.C. has served an advisory role for Pfizer. R.R.M. has served on the Advisory Board for Janssen, Novartis, and Tempus, and has received research funding from Bayer and Pfizer. Publisher Copyright: © 2018 Wiley Periodicals, Inc.

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Introduction: The 2018 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, “Tumor Cell Heterogeneity and Resistance,” was held in Los Angeles, California from June 21 to 24, 2018. Methods: The CHPCA Meeting is a unique, discussion-oriented scientific conference convened annually by the Prostate Cancer Foundation (PCF), which focuses on the most critical topics in need of further study to advance the treatment of lethal prostate cancer. The 6th Annual CHPCA Meeting was attended by 70 investigators and concentrated on prostate cancer heterogeneity and treatment resistance. Results: The meeting focused on topics including: recognition of tumor heterogeneity, molecular drivers of heterogeneity, the role of the tumor microenvironment, the role of heterogeneity in disease progression, metastasis and treatment resistance, clinical trials designed to target resistance and tumor heterogeneity, and immunotherapeutic approaches to target and overcome tumor heterogeneity. Discussion: This review article summarizes the presentations and discussions from the 2018 CHPCA Meeting in order to share this knowledge with the scientific community and encourage new studies that will lead to improved treatments and outcomes for men with prostate cancer.

AB - Introduction: The 2018 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, “Tumor Cell Heterogeneity and Resistance,” was held in Los Angeles, California from June 21 to 24, 2018. Methods: The CHPCA Meeting is a unique, discussion-oriented scientific conference convened annually by the Prostate Cancer Foundation (PCF), which focuses on the most critical topics in need of further study to advance the treatment of lethal prostate cancer. The 6th Annual CHPCA Meeting was attended by 70 investigators and concentrated on prostate cancer heterogeneity and treatment resistance. Results: The meeting focused on topics including: recognition of tumor heterogeneity, molecular drivers of heterogeneity, the role of the tumor microenvironment, the role of heterogeneity in disease progression, metastasis and treatment resistance, clinical trials designed to target resistance and tumor heterogeneity, and immunotherapeutic approaches to target and overcome tumor heterogeneity. Discussion: This review article summarizes the presentations and discussions from the 2018 CHPCA Meeting in order to share this knowledge with the scientific community and encourage new studies that will lead to improved treatments and outcomes for men with prostate cancer.

KW - biomarkers

KW - cancer immunotherapy

KW - molecular imaging

KW - therapeutics

KW - tumor genomics

UR - http://www.scopus.com/inward/record.url?scp=85055875742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055875742&partnerID=8YFLogxK

U2 - 10.1002/pros.23729

DO - 10.1002/pros.23729

M3 - Review article

C2 - 30381857

AN - SCOPUS:85055875742

SN - 0270-4137

VL - 79

SP - 244

EP - 258

JO - Prostate

JF - Prostate

IS - 3

ER -

Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this